Subcutaneous bortezomib: A step towards optimised drug use

The Lancet Oncology

Volumn 12, Issue 5, 2011, Pages 410-411

  Mateos, María Victoria ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; DEXAMETHASONE; IMMUNOMODULATING AGENT; MELPHALAN; PREDNISONE;

DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG USE; HUMAN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NOTE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; QUALITY OF LIFE; RECURRENCE;

EID: 79955445228     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70098-5     Document Type: Note

References (5)

1. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
2. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
3. Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010, 11:934-941.
4. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28:5101-5109.
5. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, published online April 19. 10.1016/S1470-2045(11)70081-X.